Kohei Hasegawa1, Jonathan M Mansbach2, Yury A Bochkov3, James E Gern3, Pedro A Piedra4, Cindy S Bauer5, Stephen J Teach6, Susan Wu7, Ashley F Sullivan1, Carlos A Camargo1. 1. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. 2. Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison. 4. Department of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, Texas. 5. Division of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, Arizona. 6. Division of Emergency Medicine and Department of Pediatrics, Children's National Health System, Washington, DC. 7. Division of Hospital Medicine, Children's Hospital of Los Angeles, Los Angeles, California.
Abstract
Importance: Rhinovirus infection in early life, particularly with allergic sensitization, is associated with higher risks of developing recurrent wheeze and asthma. While emerging evidence links different rhinovirus species (eg, rhinovirus C) to a higher severity of infection and asthma exacerbation, to our knowledge, little is known about longitudinal associations of rhinovirus C infection during infancy with subsequent morbidities. Objective: To examine the association of different viruses (respiratory syncytial virus [RSV], rhinovirus species) in bronchiolitis with risks of developing recurrent wheeze. Design, Setting, and Participants: This multicenter prospective cohort study of infants younger than 1 year who were hospitalized for bronchiolitis was conducted at 17 hospitals across 14 US states during 3 consecutive fall to winter seasons (2011-2014). Exposures: Major causative viruses of bronchiolitis, including RSV (reference group) and 3 rhinovirus species (rhinovirus A, B, and C). Main Outcomes and Measures: Development of recurrent wheeze (as defined in national asthma guidelines) by age 3 years. Results: This analytic cohort comprised 716 infants who were hospitalized for RSV-only or rhinovirus bronchiolitis. The median age was 2.9 months (interquartile range, 1.6-3.8 months), 541 (76%) had bronchiolitis with RSV only, 85 (12%) had rhinovirus A, 12 (2%) had rhinovirus B, and 78 (11%) had rhinovirus C infection. Overall, 231 (32%) developed recurrent wheeze by age 3 years. In the multivariable Cox model, compared with infants with RSV-only infection, the risk of recurrent wheeze was not significantly different in those with rhinovirus A or B (rhinovirus A: hazard ratio [HR], 1.27; 95% CI, 0.86-1.88; rhinovirus B: HR, 1.39; 95% CI, 0.51-3.77; both P > .10). By contrast, infants with rhinovirus C had a significantly higher risk (HR, 1.58; 95% CI, 1.08-2.32). There was a significant interaction between virus groups and IgE sensitization on the risk of recurrent wheeze (P for interaction < .01). Only infants with both rhinovirus C infection and IgE sensitization (to food or aeroallergens) during infancy had significantly higher risks of recurrent wheeze (HR, 3.03; 95% CI, 1.20-7.61). Furthermore, compared with RSV-only, rhinovirus C infection with IgE sensitization was associated with significantly higher risks of recurrent wheeze with subsequent development of asthma at age 4 years (HR, 4.06; 95% CI, 1.17-14.1). Conclusions and Relevance: This multicenter cohort study of infants hospitalized for bronchiolitis demonstrated between-virus differences in the risk of developing recurrent wheeze. Infants with rhinovirus C infection, along with IgE sensitization, had the highest risk. This finding was driven by the association with a subtype of recurrent wheeze: children with subsequent development of asthma.
Importance: Rhinovirus infection in early life, particularly with allergic sensitization, is associated with higher risks of developing recurrent wheeze and asthma. While emerging evidence links different rhinovirus species (eg, rhinovirus C) to a higher severity of infection and asthma exacerbation, to our knowledge, little is known about longitudinal associations of rhinovirus C infection during infancy with subsequent morbidities. Objective: To examine the association of different viruses (respiratory syncytial virus [RSV], rhinovirus species) in bronchiolitis with risks of developing recurrent wheeze. Design, Setting, and Participants: This multicenter prospective cohort study of infants younger than 1 year who were hospitalized for bronchiolitis was conducted at 17 hospitals across 14 US states during 3 consecutive fall to winter seasons (2011-2014). Exposures: Major causative viruses of bronchiolitis, including RSV (reference group) and 3 rhinovirus species (rhinovirus A, B, and C). Main Outcomes and Measures: Development of recurrent wheeze (as defined in national asthma guidelines) by age 3 years. Results: This analytic cohort comprised 716 infants who were hospitalized for RSV-only or rhinovirus bronchiolitis. The median age was 2.9 months (interquartile range, 1.6-3.8 months), 541 (76%) had bronchiolitis with RSV only, 85 (12%) had rhinovirus A, 12 (2%) had rhinovirus B, and 78 (11%) had rhinovirus C infection. Overall, 231 (32%) developed recurrent wheeze by age 3 years. In the multivariable Cox model, compared with infants with RSV-only infection, the risk of recurrent wheeze was not significantly different in those with rhinovirus A or B (rhinovirus A: hazard ratio [HR], 1.27; 95% CI, 0.86-1.88; rhinovirus B: HR, 1.39; 95% CI, 0.51-3.77; both P > .10). By contrast, infants with rhinovirus C had a significantly higher risk (HR, 1.58; 95% CI, 1.08-2.32). There was a significant interaction between virus groups and IgE sensitization on the risk of recurrent wheeze (P for interaction < .01). Only infants with both rhinovirus C infection and IgE sensitization (to food or aeroallergens) during infancy had significantly higher risks of recurrent wheeze (HR, 3.03; 95% CI, 1.20-7.61). Furthermore, compared with RSV-only, rhinovirus C infection with IgE sensitization was associated with significantly higher risks of recurrent wheeze with subsequent development of asthma at age 4 years (HR, 4.06; 95% CI, 1.17-14.1). Conclusions and Relevance: This multicenter cohort study of infants hospitalized for bronchiolitis demonstrated between-virus differences in the risk of developing recurrent wheeze. Infants with rhinovirus C infection, along with IgE sensitization, had the highest risk. This finding was driven by the association with a subtype of recurrent wheeze: children with subsequent development of asthma.
Authors: Sandy R Durrani; Daniel J Montville; Allison S Pratt; Sanjukta Sahu; Mark K DeVries; Victoria Rajamanickam; Ronald E Gangnon; Michelle A Gill; James E Gern; Robert F Lemanske; Daniel J Jackson Journal: J Allergy Clin Immunol Date: 2012-07-04 Impact factor: 10.793
Authors: Xiaoyan Lu; Brian Holloway; Ryan K Dare; Jane Kuypers; Shigeo Yagi; John V Williams; Caroline B Hall; Dean D Erdman Journal: J Clin Microbiol Date: 2007-12-05 Impact factor: 5.948
Authors: Janine Beale; Annabelle Jayaraman; David J Jackson; Sebastian L Johnston; Nathan W Bartlett; Jonathan D R Macintyre; Michael R Edwards; Ross P Walton; Jie Zhu; Yee Man Ching; Betty Shamji; Matt Edwards; John Westwick; David J Cousins; You Yi Hwang; Andrew McKenzie Journal: Sci Transl Med Date: 2014-10-01 Impact factor: 17.956
Authors: Emily K Martin; Jane Kuypers; Helen Y Chu; Kirsten Lacombe; Xuan Qin; Bonnie Strelitz; Miranda Bradford; Charla Jones; Eileen J Klein; Janet A Englund Journal: J Clin Virol Date: 2014-11-15 Impact factor: 3.168
Authors: David W Fawkner-Corbett; Siew Kim Khoo; Carminha M Duarte; Patricia G M Bezerra; Yury A Bochkov; James E Gern; Peter N Le Souef; Paul S McNamara Journal: J Med Virol Date: 2016-01 Impact factor: 2.327
Authors: Merci M H Kusel; Nicholas H de Klerk; Tatiana Kebadze; Vaike Vohma; Patrick G Holt; Sebastian L Johnston; Peter D Sly Journal: J Allergy Clin Immunol Date: 2007-03-13 Impact factor: 10.793
Authors: J David Beckham; Ana Cadena; Jiejian Lin; Pedro A Piedra; W Paul Glezen; Stephen B Greenberg; Robert L Atmar Journal: J Infect Date: 2005-05 Impact factor: 6.072
Authors: Klaus Bønnelykke; Patrick Sleiman; Kasper Nielsen; Eskil Kreiner-Møller; Josep M Mercader; Danielle Belgrave; Herman T den Dekker; Anders Husby; Astrid Sevelsted; Grissel Faura-Tellez; Li Juel Mortensen; Lavinia Paternoster; Richard Flaaten; Anne Mølgaard; David E Smart; Philip F Thomsen; Morten A Rasmussen; Silvia Bonàs-Guarch; Claus Holst; Ellen A Nohr; Rachita Yadav; Michael E March; Thomas Blicher; Peter M Lackie; Vincent W V Jaddoe; Angela Simpson; John W Holloway; Liesbeth Duijts; Adnan Custovic; Donna E Davies; David Torrents; Ramneek Gupta; Mads V Hollegaard; David M Hougaard; Hakon Hakonarson; Hans Bisgaard Journal: Nat Genet Date: 2013-11-17 Impact factor: 38.330
Authors: Michimasa Fujiogi; Carlos A Camargo; Yoshihiko Raita; Yury A Bochkov; James E Gern; Jonathan M Mansbach; Pedro A Piedra; Kohei Hasegawa Journal: Allergy Date: 2020-05-05 Impact factor: 13.146
Authors: Michimasa Fujiogi; Carlos A Camargo; Yoshihiko Raita; Yury A Bochkov; James E Gern; Jonathan M Mansbach; Pedro A Piedra; Kohei Hasegawa Journal: Pediatr Allergy Immunol Date: 2020-06-10 Impact factor: 6.377
Authors: Riku Erkkola; Riitta Turunen; Kati Räisänen; Matti Waris; Tytti Vuorinen; Miia Laine; Paula Tähtinen; James E Gern; Yury A Bochkov; Aino Ruohola; Tuomas Jartti Journal: Pediatr Infect Dis J Date: 2020-04 Impact factor: 3.806
Authors: Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Brennan Harmon; Jonathan M Mansbach; Pedro A Piedra; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa Journal: Nat Commun Date: 2021-06-14 Impact factor: 17.694
Authors: Yoshihiko Raita; Carlos A Camargo; Yury A Bochkov; Juan C Celedón; James E Gern; Jonathan M Mansbach; Eugene P Rhee; Robert J Freishtat; Kohei Hasegawa Journal: J Allergy Clin Immunol Date: 2020-11-13 Impact factor: 14.290